Association of serum asprosin with metabolic dysfunction-associated fatty liver disease in older adult type 2 diabetic patients: a cross-sectional study
BMC Endocrine Disorders · 2024
DOI: 10.1186/s12902-024-01560-1 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift BMC Endocrine Disorders, 2024. Verfasst von Junfang Cui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, The First Hospital of Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanxi Provincial Health Commission.
Abstract (Originalsprache)
Background
To explore the association of serum asprosin levels with metabolic dysfunction-associated fatty liver disease (MAFLD) in older adults with type 2 diabetes mellitus (T2DM).
Methods
The cross-sectional study enrolled patients ≥ 65 years old diagnosed with T2DM at two community health service centers between November 2019 and July 2021. Logistic regression was applied to analyze the influencing factors of MAFLD.
Results
Totally 219 cases were included. Compared with diabetic individuals without MAFLD ( n = 105), diabetics with MAFLD ( n = 114) had younger ages, higher body mass index values, shorter time from T2DM diagnosis, increased waist-to-hip ratios, elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-C), elevated alanine aminotransferase (ALT), elevated γ-glutaryl transferase, elevated fasting insulin, and elevated HOMA-IR (all P < 0.05). Serum asprosin levels were elevated in diabetics with MAFLD in comparison with the non-MAFLD group (291.71 ± 73.69 vs. 255.24 ± 82.52 pg/ml, P = 0.001). Multivariable analysis revealed, after adjusted for age, time from T2DM diagnosis, HDL-C, and ALT, serum asprosin level (OR = 1.006, 95%CI: 1.001–1.010, P = 0.014) were independently associated with MAFLD in T2DM.
Conclusions
High asprosin level are associated with MAFLD in older patients with T2DM, after adjusted for age, time from T2DM diagnosis, WHR, TG, HDL-C, ALT, GGT, FINS, and HOMA-IR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, The First Hospital of Shanxi Medical University, Taiyuan, China.
- Department of Endocrinology, The First Hospital of Shanxi Medical University, Taiyuan, China.
- Department of Endocrinology, The First Hospital of Shanxi Medical University, Taiyuan, China. yangjlm@126.com.
- Shanxi Medical University, Taiyuan, China. yangjlm@126.com.
- Department of Endocrinology, The First Hospital of Shanxi Medical University, Taiyuan, China. xulinxin_518@163.com.
Förderung
- Shanxi Provincial Health Commission
Zitieren
APA
Cui, J., Liu, Y., Li, M., Yin, J., Yang, J., & Xu, L. (2024). Association of serum asprosin with metabolic dysfunction-associated fatty liver disease in older adult type 2 diabetic patients: a cross-sectional study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-024-01560-1
Vancouver
Cui J, Liu Y, Li M, Yin J, Yang J, Xu L. Association of serum asprosin with metabolic dysfunction-associated fatty liver disease in older adult type 2 diabetic patients: a cross-sectional study. BMC Endocrine Disorders. 2024. doi:10.1186/s12902-024-01560-1
BibTeX
@article{Cui2024,
author = {Cui, Junfang and Liu, Yunfeng and Li, Mina and Yin, Jianhong and Yang, Jing and Xu, Linxin},
title = {Association of serum asprosin with metabolic dysfunction-associated fatty liver disease in older adult type 2 diabetic patients: a cross-sectional study},
journal = {BMC Endocrine Disorders},
year = {2024},
doi = {10.1186/s12902-024-01560-1}
}
EUVIMED